SubHero Banner

Lynparza® (olaparib) – New indication

May 8, 2020 - AstraZeneca announced the FDA approval of Lynparza (olaparib), in combination with bevacizumab (eg, Avastin®) for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either: a deleterious or suspected deleterious BRCA mutation, and/or genomic instability.

Download PDF